This clinical trial is focused on studying Breast Cancer and involves the use of a special imaging technique called MRI (Magnetic Resonance Imaging). The study will use a contrast agent known as gadoteric acid, which is marketed under the name DOTAREM. This contrast agent is given through an injection to help create clearer images of the breast tissue during the MRI scan.

The purpose of the study is to determine if using a lower dose of gadoteric acid with the help of advanced computer technology can provide images that are just as clear and useful for diagnosis as the standard higher dose. This approach aims to maintain the quality of the images while potentially reducing the amount of contrast agent needed.

Participants in the study will undergo a contrast-enhanced breast MRI using the reduced dose of the contrast agent. The quality of the images will be evaluated both qualitatively, which means looking at the images to see how clear they are, and quantitatively, which involves measuring specific aspects of the images. The study will also assess how well the images can help in diagnosing breast cancer. The trial is expected to continue until 2026.